• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novartis Ag ADR (NY: NVS )

    102.57 -0.12 (-0.12%)
    Official Closing Price Updated: 7:00 PM EDT, May 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 781,508
    Open 102.87
    Bid (Size) 100.18 (1)
    Ask (Size) 103.40 (1)
    Prev. Close 102.69
    Today's Range 102.50 - 102.93
    52wk Range 92.19 - 108.78
    Shares Outstanding N/A
    Dividend Yield 3.38%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
    On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
    Via Benzinga
    7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
    AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence

    Performance

    YTD
    +1.55%
    +1.55%
    1 Month
    +10.80%
    +10.80%
    3 Month
    -0.15%
    -0.15%
    6 Month
    +7.69%
    +7.69%
    1 Year
    +1.75%
    +1.75%

    More News

    Read More
    Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
    Via InvestorPlace
    Topics Intellectual Property
    Exposures Intellectual Property
    3 Magnificent Stocks That Are Passive Income Machines
    Via The Motley Fool
    Is NYSE:NVS a Good Fit for Dividend Investing?
    Via Chartmill
    Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    The 3 Best Mutual Funds to Buy in May 2024
    Via InvestorPlace
    MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
    Via Benzinga
    3 Biotech Stocks to Sell in May Before They Crash & Burn
    Via InvestorPlace
    Google DeepMind Develops Latest AI Model To Aid Scientists In Fighting Disease
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Axmed raises $2 million to transform access to critical medicines in low and middle income countries
    Via News Direct
    Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
    Via AB Newswire
    Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    2 Magnificent Dividend Stocks to Hold for the Next Decade
    Via The Motley Fool
    Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib
    Via Benzinga
    Exposures Product Safety
    AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
    Via Investor's Business Daily
    Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
    Via Talk Markets
    What's Going On With Pfizer Stock On Thursday?
    Via Benzinga
    Topics Intellectual Property
    Exposures COVID-19 Intellectual Property
    Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
    Via Investor's Business Daily
    Why Novartis Stock Topped the Market on Tuesday
    Via The Motley Fool
    FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
    Via Benzinga
    Exposures Product Safety
    NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Stocks Rally On Weaker PMI Data, Tech Earnings Optimism, Dollar Falls: What's Driving Markets Tuesday?
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.